|Systematic (IUPAC) name|
|Molar mass||403.898 g/mol|
Amibegron (SR-58,611A) is a drug developed by Sanofi-Aventis which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.
On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.
- Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008 Feb;33(3):574-87. PMID 17460614
- Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacology, Biochemistry and Behaviour. 2008 Jun;89(4):623-6. doi:10.1016/j.pbb.2008.02.020 PMID 18358519
- Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|